Mink Therapeutics, INC

MiNK Therapeutics announced first quarter 2026 financial results, highlighting the initiation of a Phase 2 trial for agenT-797 in acute lung injury and advancements in its iNKT cell therapy platform.

MiNK Therapeutics reported Q4 and full-year 2025 financial results, highlighting advancements in its Phase 2 programs for ARDS and GVHD, bolstered by significant non-dilutive funding.

MiNK Therapeutics addresses investor inquiries, confirming active discussions for agenT-797 combination trials and strategic investments.

MiNK Therapeutics announced the appointment of Melissa Orilall as Principal Financial Officer and Austin Charette as Principal Accounting Officer, effective March 13, 2026.

Dr. Robert Kadlec has resigned from MiNK Therapeutics' Board of Directors to accept a senior public service position within the U.S. government.

MiNK Therapeutics reported Q3 2025 financial results, highlighted durable clinical responses for agenT-797, expanded its iNKT platform, and strengthened its leadership team, extending its cash runway through 2026.

MiNK Therapeutics reported an increased net loss for Q3 2025, while highlighting promising clinical progress for its iNKT cell therapies and securing significant equity financing.

MiNK Therapeutics reported increased net losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern, despite advancing its iNKT cell therapy pipeline.

MiNK Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to liquidity challenges, despite ongoing clinical development and pipeline advancements.

MiNK Therapeutics reported its third quarter 2024 financial results, highlighting a decrease in operating expenses and advancements in its iNKT cell therapy programs.

MiNK Therapeutics reports a net loss of $6.5 million for the first six months of 2024, while highlighting progress in clinical trials and strategic collaborations.

MiNK Therapeutics reported a net loss of $3.8 million for the first quarter of 2024, while highlighting progress in its clinical programs and securing additional funding.

MiNK Therapeutics reported increased net losses and a going concern warning in its 2025 annual report, while highlighting promising clinical progress for its lead iNKT cell therapy, agenT-797, in oncology and pulmonary diseases.

MiNK Therapeutics details its 2024 financial results and provides an update on its clinical development programs, including agenT-797 and engineered iNKT cell therapies, along with strategic collaborations aimed at advancing cancer treatments.

MiNK Therapeutics has obtained a convertible promissory note of up to $5 million from Agenus, while also filing its annual 10-K report detailing its financial status and clinical progress.

Director Barbara Ryan sold 1,500 shares of MiNK Therapeutics, Inc. common stock on June 4, 2026.

MiNK Therapeutics Director John Bradley Holcomb reports transactions involving the acquisition of common stock and restricted stock units.

MiNK Therapeutics, Inc. reports that Director Barbara Ryan acquired shares through restricted stock units as compensation.

MiNK Therapeutics Director Brian Corvese reported transactions involving the acquisition of restricted stock units (RSUs) and common stock.

Ulf Wiinberg, a Director at MiNK Therapeutics, Inc., reported transactions involving the acquisition of common stock and restricted stock units.

Director John Bradley Holcomb was granted 4,174 stock options in MiNK Therapeutics, Inc. as part of the company's equity incentive plan.

MiNK Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 17, 2026.

MiNK Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 18, 2025, featuring proposals including director elections, an option exchange, and ratification of the company's accounting firm.

MiNK Therapeutics is seeking stockholder approval for a 1-for-10 reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement.

MiNK Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 12, 2024, featuring proposals for director elections and auditor ratification.